Phase 3 Clinical Trials With Primary Completion Dates in June 2019

This is a list of Phase 3 trials with primary completion dates in June 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
AIMTAimmune Therapeutics, Inc.2019-06-01Phase 3NCT02993107PALISADE Follow-on Study (ARC004)
ALDXAldeyra Therapeutics, Inc.2019-06-01Phase 3NCT03131154SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
ALKSAlkermes plc2019-06-01Phase 3NCT03093324A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
CCXIChemoCentryx, Inc.2019-06-01Phase 3NCT02994927A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
DMPIDelMar Pharmaceuticals, Inc.2019-06-01Phase 3NCT03149575VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
ICLRICON plc2019-06-01Phase 3NCT02586155Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
ITCIIntra-Cellular Therapies Inc.2019-06-01Phase 3NCT03249376Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
ITCIIntra-Cellular Therapies Inc.2019-06-01Phase 3NCT02600494Clinical Trial Evaluating ITI-007 as a Monotherapy for the Treatment of Bipolar Depression
KMPHKemPharm, Inc.2019-06-01Phase 3NCT03460652KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
SLNOSoleno Therapeutics, Inc.2019-06-01Phase 3NCT03440814A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
TGTXTG Therapeutics, Inc.2019-06-01Phase 3NCT02301156Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
ZGNXZogenix, Inc.2019-06-01Phase 3NCT02682927A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome